Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) just unveiled an update.
ResMed Inc. has announced a proposed sale of securities under Rule 144, with Michael J. Farrell, an officer and director of the company, planning to sell 8,009 shares of common stock. The sale is expected to occur on July 7, 2025, with the aggregate market value of the shares estimated at approximately $2,056,075.99. This transaction follows previous sales by Farrell in April and May 2025, which generated gross proceeds of over $3.6 million. The announcement may impact stakeholder perceptions and market dynamics, given Farrell’s significant role within the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of products and solutions for sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is known for its innovative medical devices and cloud-connected software applications, which aim to improve patient health outcomes and reduce the cost of healthcare delivery.
Average Trading Volume: 1,063,434
Technical Sentiment Signal: Buy
Current Market Cap: A$57.7B
See more data about RMD stock on TipRanks’ Stock Analysis page.